Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting
Teva scraps Heptares migraine pact as lead drug nears clinic | Fierce Biotech
Fed Circ. upholds some Teva migraine drug patents, invalidates others | Reuters
Teva's recalled migraine medicine Zecuity has a long local history - Philadelphia Business Journal
Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | Business Wire
Boston Jury Awards Teva Pharmaceuticals $176.5M for Eli Lilly's Migraine Medication Patent Infringement | Law.com
Eli Lilly (NYSE:LLY) Loses Migraine Drug Patent Trial to Teva
Teva Pharmaceutical Industries Ltd. - New research by Teva has thrown a spotlight on how badly affected women are by #migraine. But behind those numbers are real people. Come and meet some
Teva v. Eli Lilly: Teva argues Lilly is infringing migraine drug patent in the United States - Harvard Journal of Law & Technology
Teva Wins Three, Loses Six in Patent Battle Over Migraine Drug – PharmaLive
FDA approves Vyepti, first IV preventive treatment for migraine
Ajovy, Teva's migraine drug, recommended by UK's NICE.
Teva's migraine med given marketing authorization
Teva stops selling migraine patch after reports of burns
Eli Lilly avoids sanctions in Teva migraine treatment dispute
AbbVie, Biohaven, Teva and Satsuma tackle migraine at AHS – PharmaLive
Teva Halts Phase III Trial of Fremanezumab in Chronic Cluster Headaches
Teva tackles migraine through potential $400m Heptares collaboration
Xconomy: Teva Migraine Drug Likely Delayed by Manufacturing Trouble
Teva Canada Announces Product Availability of AJOVY™ | Business Wire
FDA approves Teva's migraine injection AJOVY™ - Pf Media
